Xiaoyi Hu , Asiri Ediriwickrema , Atif Saleem , Brent Tan , Naveen Pemmaraju , Gabriel N. Mannis
{"title":"CD38和BCL2的表达为达拉单抗和venetoclax治疗以CD123动态缺失为特征的tagraxofusp难治性大疱性浆细胞性树突状细胞瘤(BPDCN)提供了指导","authors":"Xiaoyi Hu , Asiri Ediriwickrema , Atif Saleem , Brent Tan , Naveen Pemmaraju , Gabriel N. Mannis","doi":"10.1016/j.leukres.2024.107479","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"139 ","pages":"Article 107479"},"PeriodicalIF":2.1000,"publicationDate":"2024-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123\",\"authors\":\"Xiaoyi Hu , Asiri Ediriwickrema , Atif Saleem , Brent Tan , Naveen Pemmaraju , Gabriel N. Mannis\",\"doi\":\"10.1016/j.leukres.2024.107479\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":18051,\"journal\":{\"name\":\"Leukemia research\",\"volume\":\"139 \",\"pages\":\"Article 107479\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-03-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0145212624000456\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0145212624000456","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123
期刊介绍:
Leukemia Research an international journal which brings comprehensive and current information to all health care professionals involved in basic and applied clinical research in hematological malignancies. The editors encourage the submission of articles relevant to hematological malignancies. The Journal scope includes reporting studies of cellular and molecular biology, genetics, immunology, epidemiology, clinical evaluation, and therapy of these diseases.